BoomRx expands women’s hormone therapy options for physicians

BoomRx is spotlighting more than 24 bioidentical hormone-replacement therapy options for women through its prescription portal, giving licensed providers a wider menu of dosage forms and fulfillment choices. The company says the offering is designed to simplify pharmacy workflows for practices handling hormone-related care.

Why it matters: - Women’s hormone care often requires tailored dosing, multiple delivery formats, and pharmacy coordination that can slow down treatment decisions. - BoomRx is positioning its portal as a way for practices to manage those workflows through a single system while keeping prescribing decisions with licensed clinicians.

What happened: - BoomRx said July 15, 2026, that it is highlighting more than 24 bioidentical hormone-replacement therapies for women through its pharmacy portal. - The company says the portfolio is available to healthcare providers who need flexible, more personalized treatment protocols. - BoomRx also said the offerings are intended for licensed healthcare providers and practice teams, not patients directly.

The details: - The women’s hormone-health lineup includes estrogen, estriol, estradiol, Bi-Est formulations, progesterone, estrogen-progesterone combinations, DHEA, pregnenolone, testosterone where clinically appropriate, thyroid-related therapies, and wellness-support options. - Available delivery forms include topical creams and gels, oral capsules and tablets, rapid-dissolve and orally disintegrating tablets, troches and sublingual options, vaginal creams, inserts and suppositories, injectables, patches, and supporting injection-supply kits. - Additional wellness-focused options may include nasal and oral delivery formats, depending on the therapy and prescribing need. - Bioidentical hormones are manufactured from plant compounds, primarily derived from soybeans and wild yams, and are chemically identical to hormones naturally produced by the human body. - BoomRx says practices can review available options, place orders, and coordinate fulfillment through one platform instead of managing separate pharmacy relationships. - The platform supports women’s care clinics, general practitioners, OB-GYN practices, telehealth organizations, longevity and wellness centers, functional medicine practices, med spas, and other healthcare organizations that manage prescription workflows for hormone-related care. - BoomRx says it does not diagnose, prescribe, or recommend treatment directly to patients. - Treatment decisions remain with licensed healthcare providers based on each patient’s clinical needs, applicable laws, and professional judgment.

Between the lines: - BoomRx is trying to make women’s hormone therapy look less like a single-product category and more like a configurable clinical workflow. - The pitch is as much about operational simplification as it is about product breadth, which could matter to practices juggling staff time, fulfillment, and patient communication. - The company’s broader platform is built around consolidating multi-pharmacy workflows, reducing state-by-state shipping complexity, expanding national access, offering flat-rate shipping, and improving price transparency.

What's next: - BoomRx will likely use the expanded therapy menu to deepen adoption among practices that already handle hormone-related care and to attract new provider users. - The company is continuing to market its single secure ordering portal for regulated 503A and FDA-registered 503B outsourcing facility products, as well as other manufactured and brand medications.

The bottom line: - BoomRx is betting that more prescribing options and simpler pharmacy logistics will help practices deliver more personalized hormone care with less administrative friction.